Shilpa Medicare Ltd

Encumbrance release details

• Target company: Shilpa Medicare Limited.
• Encumbrance released: 30,00,000 shares, 1.5337% of paid-up capital.
• Date of release: 25-09-2026; nature: release of pledged shares.
• Promoter group: Vishnukant C Bhutada; Dharmavati Bhutada; Deepak Kumar Innani; Ramakant Innani; Om Prakash Inani; Brijgopal Innani.
• Favouring entity: Bajaj Finance Limited.
• Reason: encumbrance created as collateral for self-loan.
• Post-release encumbrance percentages range from 0.10225% to 0.5113%.

Shilpa Medicare Limited – Closure of Trading Window from 01 October 2026 until 48 hours after the declaration of un-audited Financial Results for quarter and half year ended 30 September 2026

Shilpa Medicare Limited: Trading Window closure from 01 October 2026 till 48 hours after the declaration of un-audited Financial Results for quarter and half year ended 30 September 2026

ESG rating assignment

• CRISIL ESG Ratings assigned ESG score 59 to Shilpa Medicare Limited.
• Rating prepared independently based on fiscal 2026 disclosures and public data.
• Company has not engaged CRISIL ESG Ratings for this assessment.
• Disclosure is under Regulation 30 and SEBI Circular dated 30 January 2026.
• Summary report received on 22 September 2026 for information and records.

Meeting Details

• Date: 28 September 2026
• Event: Nuvama Emerging India CEO Forum
• Type/Mode: In-person; 1x1 and group meetings
• Location: Mumbai
• Purpose: Investor conference participation and investor meetings
• Note: No UPSI will be shared during the meeting

Meeting Details

• Date: 28 September 2026
• Event: Nuvama Emerging India CEO Forum
• Location: Mumbai
• Type: In-person
• Meeting format: 1x1 and group meetings

USFDA inspection outcome

• USFDA conducted surveillance inspection at Unit VII, Analytical Services Division, Hyderabad, 16–18 Sep 2026.
• One procedural observation issued; not related to data integrity or repeat observation.
• Company to submit comprehensive response within the stipulated timeline, with corrective actions.
• No material impact expected on current operations or existing supplies from this facility.
• Annexure A provides details; information also available on the company's website.

AGM Details

• AGM held on 11 September 2026 at 11:00 IST via VC/OAVM.
• Voting cut-off date: 4 September 2026.
• Remote e-voting window: 7–10 September 2026.

Resolutions — Ordinary

• Adoption of audited standalone and consolidated financials for year ended 31 March 2026.
• Declaration of final dividend of Rs 0.60 per equity share.
• Reappointment of director on rotation.
• Ratification of remuneration of Cost Auditors.
• Payment of commission to NED Bhutada and to Material Subsidiary Shilpa Biologicals.

Voting results by resolution

• Res 1 passed with 100% in-favour; abstentions noted.
• Res 2 passed with 100% in-favour; minimal abstentions.
• Res 3 passed with 99.38% in-favour; 0.62% against.
• Res 4 passed with 100% in-favour.
• Res 5 passed with 88.80% in-favour; 11.20% against.

Dividend

• Final dividend of Rs 0.60 per equity share approved.

Director changes

• Director reappointed on rotation.

Auditor remuneration

• Cost Auditor remuneration ratified.

Material related party transactions

• Approval of commission payments to NED Bhutada and to Shilpa Biologicals (material subsidiary).

Regulatory approval and launch plan for OERIS

• SEC under CDSCO granted final marketing authorization for OERIS™ (Ondansetron Extended-Release Injection, 100 mg/mL).
• OERIS provides antiemetic action for up to 120 hours (5 days) after a single dose.
• India launch planned; patent protection in India till 2039.
• Approval based on Phase III multicenter randomized double-blind trial for chemotherapy-induced nausea and vomiting.
• Single-dose every five days reduces injections, improving patient convenience and healthcare staff efficiency.
• Commercial launch across India to commence upon CDSCO final authorization.
• OERIS is the world's first extended-release ondansetron injectable formulation.